Kelly K
University of Colorado Cancer Center, Denver, CO, USA.
Clin Lung Cancer. 2001 May;2 Suppl 2:S4-8. doi: 10.3816/clc.2001.s.001.
Irinotecan, a new topoisomerase I inhibitor, has significant activity in the treatment of untreated and previously treated patients with small-cell lung cancer (SCLC). In combination with cisplatin, a Japanese randomized trial showed a statistically significant survival advantage over cisplatin/etoposide in chemotherapy- naive patients with extensive-stage disease. This represents the first major advance in the treatment of extensive-stage SCLC in 20 years. Randomized trials in the United States are underway to confirm these impressive results. Meanwhile, trials incorporating irinotecan and cisplatin into treatment regimens for limited-stage disease are being conducted. Furthermore, irinotecan-containing regimens with other agents such as carboplatin, etoposide, and paclitaxel in first- or second-line therapies for SCLC are being evaluated. Preliminary results are encouraging. This article will highlight the exciting results achieved with irinotecan in SCLC and discuss its promising future in this disease.
伊立替康是一种新型拓扑异构酶I抑制剂，在治疗未经治疗和先前接受过治疗的小细胞肺癌（SCLC）患者方面具有显著活性。在与顺铂联合使用时，一项日本随机试验表明，对于广泛期疾病的初治患者，与顺铂/依托泊苷相比，在统计学上具有显著的生存优势。这是20年来广泛期小细胞肺癌治疗方面的首个重大进展。美国正在进行随机试验以证实这些令人印象深刻的结果。与此同时，正在开展将伊立替康和顺铂纳入局限期疾病治疗方案的试验。此外，正在评估含伊立替康的方案与卡铂、依托泊苷和紫杉醇等其他药物联合用于小细胞肺癌一线或二线治疗的情况。初步结果令人鼓舞。本文将重点介绍伊立替康在小细胞肺癌治疗中取得的令人振奋的结果，并讨论其在该疾病治疗中充满希望的未来。
